SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize care based on each patient’s tumor biology, are derived from research using Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) tool.

加利福尼亚州南旧金山市——（商业新闻短讯）——领先的癌症诊断公司Veracyte，Inc.（纳斯达克：VCYT）今天宣布了新的研究结果，表明新的分子标记有可能识别患有甲状腺结节或侵袭性疾病的癌症患者。这些发现可能有助于临床医生根据每位患者的肿瘤生物学进一步个性化护理，这些发现来自使用Veracyte的Afirma GRID（智能发现基因组资源）工具进行的研究。

The results were presented today at ENDO 2024, the annual meeting of The Endocrine Society in Boston..

研究结果于今天在波士顿举行的内分泌学会年会ENDO 2024上公布。。

“Clinicians generally want to avoid overtreatment of patients with non-aggressive thyroid tumors while targeting more-intensive treatment to those patients with aggressive disease. The challenge is distinguishing between them, especially given the heterogeneity of thyroid tumors,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology.

Veracyte内分泌医学主任约书亚·科洛珀（JoshuaKlopper）说：“临床医生通常希望避免过度治疗非侵袭性甲状腺肿瘤患者，同时针对侵袭性疾病患者进行更深入的治疗。挑战在于区分它们，特别是考虑到甲状腺肿瘤的异质性。”。

“The studies presented at ENDO 2024 today show how our Research-Use-Only Afirma GRID tool, which leverages our whole-transcriptome-derived testing approach, is helping scientists better understand important nuances in the molecular underpinnings of thyroid tumors. These insights may ultimately enable more-personalized care for patients.”.

“今天在ENDO 2024上发表的研究表明，我们的研究如何仅使用Afirma网格工具，该工具利用了我们的整个转录组衍生的测试方法，帮助科学家更好地了解甲状腺肿瘤分子基础中的重要细微差别。这些见解可能最终为患者提供更个性化的护理。”。

Following are highlights of the three Afirma GRID-focused studies presented at the ENDO 2024 conference:

以下是在ENDO 2024会议上提出的三项以Afirma电网为重点的研究的重点：

Poster presentation (MON-640): Retrospective Analysis of mRNA Expression Based Signatures of Thyroid Tumor Invasion and Metastases. Presented by Sara Ahmadi, M.D., Brigham and Women’s Hospital.

海报展示（MON-640）：回顾性分析甲状腺肿瘤侵袭和转移的基于mRNA表达的特征。由布莱根妇女医院医学博士萨拉·艾哈迈迪介绍。

Summary: Researchers analyzed novel whole-transcriptome-based signatures, previously presented at the ENDO 2023 meeting, that were designed to help rule out significant thyroid tumor invasion or regional lymph node metastases in patients with indeterminate thyroid nodules. This was a retrospective study of 203 thyroid nodule patients with indeterminate cytology who had Afirma GSC-suspicious results and pathology results from subsequent thyroid surgery.

总结：研究人员分析了先前在ENDO 2023会议上提出的基于全转录组的新型特征，这些特征旨在帮助排除甲状腺结节不确定患者的显着甲状腺肿瘤侵袭或区域淋巴结转移。这是一项回顾性研究，对203例细胞学不确定的甲状腺结节患者进行了回顾性研究，这些患者的FIRMA GSC可疑结果和随后甲状腺手术的病理结果。

The molecular signatures ruled out the clinically significant features in more than 50% of patients, with a greater than 95% negative predictive value..

分子特征排除了50%以上患者的临床显着特征，阴性预测值大于95%。。

“Today, most patients with thyroid nodules that are suspicious for cancer are directed to surgery,” said Sara Ahmadi, M.D., of Brigham and Women’s Hospital who presented the findings. “Our results suggest that molecular testing may potentially help to further stratify risk so that clinicians could confidently perform a less-invasive surgical procedure that would reduce complications and potentially mitigate the need for lifelong thyroid hormone replacement therapy.

Brigham and Women's Hospital的医学博士萨拉·艾哈迈迪（SaraAhmadi）介绍了这一发现，她说：“今天，大多数疑似癌症的甲状腺结节患者都要接受手术治疗。”。“我们的研究结果表明，分子检测可能有助于进一步分层风险，以便临床医生可以自信地进行侵入性较小的外科手术，从而减少并发症，并可能减轻终身甲状腺激素替代治疗的需要。

While more study is needed, these findings are an exciting step towards the future of personalized medicine in thyroid nodules and cancer.”.

虽然需要更多的研究，但这些发现是迈向甲状腺结节和癌症个性化医学未来的令人兴奋的一步。”。

Oral presentation (OR28-04): Cancer-associated Fibroblasts Correlate with Aggressive Thyroid Cancer Behavior: Insights from Four Large Patient Cohorts. Presented by Matthew A. Loberg, B.A., Vanderbilt University Medical Center.

口腔介绍（OR28-04）：癌症相关成纤维细胞与侵袭性甲状腺癌行为相关：来自四个大型患者队列的见解。由范德比尔特大学医学中心的Matthew A.Loberg博士介绍。

Summary: Researchers identified cancer-associated fibroblasts (CAFs) in the thyroid tumor microenvironment that correlate with aggression in thyroid cancers largely by leveraging the Afirma GRID database, which includes whole-transcriptome data derived from the Afirma assay. In this multicenter study involving nearly 50,000 patients, they identified CAFs for the first time in pre-operative fine needle aspiration (FNA) samples.

总结：研究人员主要通过利用Afirma网格数据库（其中包括来自Afirma测定的全转录组数据）在甲状腺肿瘤微环境中鉴定了与甲状腺癌侵袭相关的癌症相关成纤维细胞（CAF）。在这项涉及近50000名患者的多中心研究中，他们首次在术前细针穿刺（FNA）样本中鉴定出CAF。

Notably, they found that the SFRP2+ CAF was associated with shorter progression-free survival, tumor invasion and lymph node metastasis. It was also enriched in thyroid nodules that were deemed suspicious by the Afirma Genomic Sequencing Classifier (GSC) or Bethesda V/VI by cytopathology, compared to Afirma GSC-benign nodules.

值得注意的是，他们发现SFRP2+CAF与较短的无进展生存期，肿瘤侵袭和淋巴结转移有关。与Afirma GSC良性结节相比，它还富含被Afirma基因组测序分类器（GSC）或Bethesda V/VI通过细胞病理学认为可疑的甲状腺结节。

While more study is needed, such insights could potentially help inform more-personalized management strategies for patients with thyroid nodules or cancer..

虽然需要更多的研究，但这些见解可能有助于为甲状腺结节或癌症患者提供更个性化的管理策略。。

Poster Presentation (MON-649) and Rapid-Fire Oral Presentation (RF28-01): Prostate-specific Membrane Antigen (PSMA) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules. Presented by Rabail Sadiq, M.B.B.S., Johns Hopkins University School of Medicine.

海报展示（MON-649）和Rapid Fire口腔展示（RF28-01）：前列腺特异性膜抗原（PSMA）在细胞学不确定和恶性甲状腺结节中的表达。由约翰·霍普金斯大学医学院医学博士Rabail Sadiq介绍。

Prostate-specific membrane antigen (PSMA) is a protein found on the surface of cancer cells and is increasingly used as a biomarker in prostate cancer detection and treatment. Higher PSMA levels have also been associated with more-aggressive thyroid cancers. Researchers leveraged the Afirma GRID database to characterize the expression of PSMA (FOLH1) in a cohort of nearly 50,000 thyroid nodules sent for Afirma GSC molecular testing.

前列腺特异性膜抗原（PSMA）是一种在癌细胞表面发现的蛋白质，越来越多地被用作前列腺癌检测和治疗的生物标志物。较高的PSMA水平也与更具侵袭性的甲状腺癌有关。研究人员利用Afirma网格数据库来表征PSMA（FOLH1）在近50000个甲状腺结节中的表达，这些结节被送往Afirma GSC分子检测。

They found that PSMA gene expression was higher in indeterminate nodules that were Afirma GSC-suspicious and in nodules whose cytopathology was classified as Bethesda V/VI, compared to Afirma GSC-benign nodules. They also found variability in PSMA expression in the context of certain molecular driver mutations.

他们发现，与Afirma GSC良性结节相比，在Afirma GSC可疑的不确定结节和细胞病理学分类为Bethesda V/VI的结节中，PSMA基因表达更高。他们还发现在某些分子驱动突变的背景下，PSMA表达存在差异。

The authors conclude that PSMA expression may potentially help provide further prognostic information to inform care for thyroid nodule patients..

作者得出结论，PSMA表达可能有助于提供进一步的预后信息，为甲状腺结节患者的护理提供信息。。

“The studies presented at ENDO 2024 reinforce our commitment to not only developing high-performing tests, but also to helping the research community advance the science around thyroid cancer and the other indications we serve,” said Phillip Febbo, M.D., chief scientific officer and chief medical officer at Veracyte.

Veracyte首席科学官兼首席医疗官Phillip Febbo医学博士说：“在ENDO 2024上提出的研究不仅加强了我们对开发高性能测试的承诺，而且还帮助研究界推进甲状腺癌和我们服务的其他适应症的科学。”。

“They also demonstrate the power of our Veracyte Diagnostics Platform, through which our comprehensive, whole-transcriptome-derived testing approach helps drive continued innovation to ultimately help more patients.”.

“他们还展示了我们的Veracyte诊断平台的强大功能，通过该平台，我们全面的全转录组衍生测试方法有助于推动持续创新，最终帮助更多患者。”。

About Afirma GRID

关于Afirma网格

The Afirma GRID database is derived from the sequencing of over 21,000 expressed genes for nearly 200,000 patients with thyroid nodules (benign and malignant) and is used by Veracyte and its partners to contribute to continued research that helps advance understanding of thyroid tumors. Afirma GRID information is available on a Research-Use-Only basis.

Afirma GRID数据库来自对近200000名甲状腺结节（良性和恶性）患者的21000多个表达基因的测序，Veracyte及其合作伙伴将其用于促进对甲状腺肿瘤的进一步研究。Afirma网格信息仅供研究使用。

More information about Afirma GRID can be found here..

关于Afirma网格的更多信息可以在这里找到。。

About the Afirma GSC

关于Afirma GSC

Veracyte’s flagship Afirma Genomic Sequencing Classifier (GSC) was developed with RNA whole-transcriptome-derived sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery.

Veracyte的旗舰Afirma基因组测序分类器（GSC）是使用RNA全转录组衍生测序和机器学习技术开发的，可帮助医生在细针穿刺（FNA）活检结果不确定的细胞病理学患者中识别良性甲状腺结节患者，从而可以避免不必要的甲状腺手术。

The Afirma GSC also includes Xpression Atlas, the largest thyroid gene and fusion variant panel available, to help inform treatment decisions for patients whose genomic test or cytopathology results are suspicious for cancer. Veracyte also enables physicians to order DNA testing of the TERT promoter gene, which is performed on the same FNA sample, to help further guide treatment decision-making.

Afirma GSC还包括Xpression Atlas，这是可用的最大的甲状腺基因和融合变异面板，可帮助为基因组测试或细胞病理学结果可疑癌症的患者提供治疗决策。Veracyte还使医生能够对同一FNA样本进行TERT启动子基因的DNA测试，以帮助进一步指导治疗决策。

More information about the Afirma GSC can be found here..

关于Afirma GSC的更多信息可以在这里找到。。

About Veracyte

关于Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development.

Veracyte（纳斯达克股票代码：VCYT）是一家全球诊断公司，其愿景是为全世界的患者转变癌症护理。我们为临床医生提供所需的高价值见解，以指导和确保患者在诊断和治疗癌症的关键时刻。我们的Veracyte诊断平台提供了高性能的癌症测试，这些测试由广泛的基因组和临床数据，深入的生物信息学和人工智能能力以及强大的证据生成引擎提供支持，最终推动了我们测试的持久报销和指南纳入，以及支持持续创新和管道开发的新见解。

For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte..

欲了解更多信息，请访问www.veracyte.com，并在X（原推特）上关注该公司@veracyte。。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release contains forward-looking statements, including, but not limited to our statements related to the potential for the Afirma GRID research-use-only tool to help scientists better understand important nuances in the molecular underpinnings of thyroid tumors, such insights which may ultimately enable more-personalized care for patients.

本新闻稿包含前瞻性声明，包括但不限于我们与Afirma网格研究潜力相关的声明，该研究仅用于帮助科学家更好地了解甲状腺肿瘤分子基础中的重要细微差别，这些见解可能最终使患者获得更个性化的护理。

Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” 'ultimately,' and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements.

前瞻性陈述可以用“出现”、“预期”、“打算”、“计划”、“预期”、“相信”、“应该”、“可能”、“将”、“启用”、“定位”、“提供”、“设计”、“最终”等词语来识别，以及类似的未来时期的引用。实际结果可能与任何前瞻性声明中预测或建议的结果存在重大差异。

These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact Afirma GRID can have on scientific advancements in thyroid cancer and, in turn, patients. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 29, 2024, and our 10-Q filed on May 8, 2024.

这些陈述涉及风险和不确定性，这可能导致实际结果与我们的预测有实质性差异，包括但不限于IRMA网格对甲状腺癌以及患者的科学进步的潜在影响。可能影响这些前瞻性陈述的其他因素可以在我们2024年2月29日提交的10-K表年度报告和2024年5月8日提交的10-Q表中的“风险因素”标题下找到。

Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

这些文件的副本（如有）可在我们网站的投资者部分找到，网址为https://investor.veracyte.com.这些前瞻性声明仅在本协议签署之日有效，除法律要求外，我们明确否认有义务更新这些前瞻性声明或实际结果可能不同的原因，无论是由于新信息、未来事件或其他原因。

These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements.

这些前瞻性声明仅在本协议签署之日有效，除法律要求外，我们明确否认更新这些前瞻性声明的任何义务。

Veracyte, the Veracyte logo, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

Veracyte、Veracyte徽标和Afirma是Veracyte，Inc.及其子公司在美国和选定国家的注册商标。